| Document |
Document Title |
|
WO/2018/170166A1 |
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of condi...
|
|
WO/2018/167695A1 |
The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof. It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular t...
|
|
WO/2018/167468A1 |
The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein inhibit the matura...
|
|
WO/2018/167800A1 |
The present invention relates to fused bicyclic compounds that are inhibitors of GPR91, their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions containing them. T...
|
|
WO/2018/165501A1 |
The invention provides aryl indolinyl sulfonamide and related compounds, pharmaceutical compositions, methods of promoting RORγ activity and/or increasing the amount of IL-17 in a subject, and therapeutic uses of the indolinyl sulfonami...
|
|
WO/2018/165466A1 |
Disclosed are Indole and Indazole urea derivative compounds, methods for preparing these compounds, and methods for treating cancer.
|
|
WO/2018/162793A1 |
The present invention relates to crystalline particles of N-((S)-l-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan
-2-yl)-5-(1-hydroxyethyl)-1 H-pyrazole-3-carboxamide (I) having specific surface area (SSA) in the range from about 8 ...
|
|
WO/2018/157842A1 |
The present invention provides a use of 2-(substituted phenylamino)benzoic acid FTO inhibitor in treating leukemia.
|
|
WO/2018/160618A1 |
Substituted hydroquinones, 1,4-quinones, catechols, 1,2-quinones, anthraquinones, and anthrahydroquinones are disclosed herein. The substituted hydroquinones and catechols have the formula: while the substituted 1,4-quinones or 1,2-have ...
|
|
WO/2018/157843A1 |
The preparation method provides 2-(substituted benzene matrix) aromatic formate FTO inhibitor, a preparation method therefor, and applications thereof. Specifically, disclosed in the present invention are a 2-(substituted benzene matrix)...
|
|
WO/2018/158212A1 |
The present invention is directed to pyrazole derivatives, pharmaceutical compositions comprising the compounds and the use of the compounds or the compositions in the treatment of various diseases
|
|
WO/2018/161033A1 |
Described herein are IRE1-alpha inhibitors, compositions containing such inhibitors, and methods of treatment of cancer that include administration of such compounds. Exemplary compounds are provided throughout the application.
|
|
WO/2018/158620A1 |
The present invention provides processes for the preparation of active pharmaceutical ingredients and intermediates thereof in an aqueous designer smart surfactant solution.
|
|
WO/2018/159827A1 |
The present invention provides a novel non-steroid-type compound or a salt thereof, having BR-like activity which is useful for regulating plant growth, an agricultural composition containing the compound or the salt thereof, and uses th...
|
|
WO/2018/159639A1 |
Provided is a method for producing a heterocyclic compound which is useful as a prophylactic and/or therapeutic agent for Alzheimer's disease and the like. A method for producing 1,5-anhydro-2,4-dideoxy-2-(4-fluoro-5-methyl-1-oxo-6-(4-(1...
|
|
WO/2018/153707A1 |
The present invention relates to crystalline forms of the strobilurin-type compound (Z,2E)-5-[1-(2,4-dichlorophenyl)pyrazol-3-yl]oxy-2 methoxyimino-N,3-dimethyl-pent-3-enamide and to processes for their preparation and agrochemical compo...
|
|
WO/2018/154097A1 |
The invention discloses a method for the preparation of 1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-ol with high selectivity with respect to the content of the isomer 1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-ol, wherein ethyl 4,4,4-triflu...
|
|
WO/2018/154519A1 |
The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compo...
|
|
WO/2018/033642A9 |
The present invention relates to a compound of formula (I): wherein L is an optionally substituted heterocyclic group excluding unsubstituted monocyclic pyridine groups; wherein a is 0, 1 or 2; wherein R1 is H or with R2 is a bond; where...
|
|
WO/2018/151126A1 |
The present invention addresses the problem of providing: a novel method for producing an indazole compound, which is capable of producing an indazole compound without using a reaction reagent that has high toxicity; and a novel indazole...
|
|
WO/2018/149813A1 |
The present invention relates to a process for preparing substituted 2-nitrobiphenyls via Suzuki coupling using a palladium catalyst with specific phosphorus ligands and a solvent mixture containing water and an organic solvent which is ...
|
|
WO/2018/150061A1 |
The invention relates to novel functionalised polymers of formula (I), in which trispyrazolylborate-type ligands attach to the structure of vinyl polynorbornenes. In this way, the novel polymer compound can form coordination compounds wi...
|
|
WO/2018/145653A1 |
The present invention relates to the technical field of chemical medicine and relates to a compound represented by formula (I) or formula (II) and a preparation method therefor, the compound being a biaryl derivative and having retinoid-...
|
|
WO/2018/148737A1 |
The present invention is directed to the use of a 5-HT2A serotonin receptor inverse agonist for the prophylaxis and/or treatment of the symptoms of dementia with Lewy bodies, Parkinson's disease, or a combination thereof in an individual...
|
|
WO/2018/141069A1 |
Methods of detecting an aldehyde-containing compound in a subject or in a sample from a subject are described herein, comprising administering an aldehyde-binding compound of Formula I to the subject, or combining such a compound with th...
|
|
WO/2018/141751A1 |
The invention relates to an economical, single-stage method for producing n-substituted aromatic hydroxylamine of formula (I) R-N(OH)-C(=O)-(O) R1 (I), using hydrogen, by catalytic hydrogenation using optionally modified hydrogenation ca...
|
|
WO/2018/139174A1 |
A fluoroether compound represented by formula (1). R1-R2-CH2-R3-CH2-R4-R5 (1) (In formula (1), R1 and R5 may be the same or different and are each a group having a heteroring, R2 and R4 may be the same or different and are each a divalen...
|
|
WO/2018/140512A1 |
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): (I) or a pharmaceutically acceptable salt, isotopic form, stereoisomer or prodrug thereof, wherein A, B, X,...
|
|
WO/2018/137593A1 |
Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase a...
|
|
WO/2018/138362A1 |
The present invention provides e.g. N-{[2-(piperidin-1-yl)phenyl] (phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)
acetamide derivatives and related compounds as ROR-gamma modulators for treating e.g. autoimmune diseases, aut...
|
|
WO/2018/137618A1 |
Compounds of Formula (I) or pharmaceutically acceptable salt thereof, a pharmaceutical compositions comprising these compounds, the use of these compounds and compositions in the treatment of diseases in which LRRK-2 kinase is involved.
|
|
WO/2018/136890A1 |
The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLR...
|
|
WO/2018/133818A1 |
Provided are a method for preparing bicyclo-substituted pyrazolone azo derivatives and intermediates thereof.
|
|
WO/2018/133621A1 |
An edaravone derivative and a use thereof. As compared with edaravone, the derivative has enhanced treatment effects and significantly reduced cytotoxicity.
|
|
WO/2018/133870A1 |
A compound represented by formula (I), a pharmaceutically acceptable salt or tautomer thereof, and an application of the compound as a caspase inhibitor.
|
|
WO/2018/132372A1 |
Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.
|
|
WO/2018/123918A1 |
Provided is a compound or a salt thereof, represented by the formula shown, which has a RORγt inhibitory effect and is useful as a preventive or therapeutic agent for autoimmune diseases, allergies, and the like.
|
|
WO/2018/125816A1 |
This application relates to efficient and economical synthetic chemical processes for the preparation of pesticidal thioethers and pesticidal sulfoxides. Further, the present application relates to certain novel compounds necessary for t...
|
|
WO/2018/124088A1 |
Provided are novel pest control agents, in particular, a bactericide and a nematicide. An alkylphenyl-substituted amide compound represented by formula (I) [wherein: G1 stands for a structure represented by G1-2, G1-3, G1-4, etc.; X1 sta...
|
|
WO/2018/122212A1 |
Compounds of Formula (IA), or a pharmaceutically acceptable salt thereof, and methods of use as Janus kinase inhibitors are described herein.
|
|
WO/2018/121689A1 |
The present invention provides a sulfonamide-aryl amide compound and a use thereof as a drug for treating hepatitis B. Particularly, the present invention provides a compound as an HBV replication inhibitor and having the structure shown...
|
|
WO/2018/125877A1 |
Stable solid fungicidal compositions containing valifenalate, cymoxanil and mancozeb are disclosed. Also disclosed are methods for curing or preventing a fungal disease, including an Oomycete-related disease, using the solid fungicidal c...
|
|
WO/2018/125817A1 |
This application relates to efficient and economical synthetic chemical processes for the preparation of pesticidal thioethers. Further, the present application relates to certain novel compounds useful in the preparation of pesticidal t...
|
|
WO/2018/125820A1 |
The disclosure relates to efficient and economical synthetic chemical processes for the preparation of pesticidal thioethers. Further, the disclosure relates to certain novel compounds useful in the preparation of pesticidal thioethers.
|
|
WO/2018/125815A1 |
This application relates to efficient and economical synthetic chemical processes for the preparation of pesticidal thioethers and pesticidal sulfoxides. Further, the present application relates to certain novel compounds necessary for t...
|
|
WO/2018/119262A1 |
Compositions and methods for treating glioblastoma or recurrent glioblastoma and its associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[l,5- a]pyridine) or a pharmaceutically acceptable salt thereof.
|
|
WO/2018/114786A1 |
The present invention relates to carboxylic acid aromatic amides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds...
|
|
WO/2018/116107A1 |
Provided are IDO inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases ...
|
|
WO/2018/117151A1 |
The present invention relates to: a method for producing a 7H-pyrrolo[2,3-d]pyrimidine derivative which is useful as a Janus kinase (JAK) inhibitor; a cocrystal of the derivative; a method for producing the cocrystal; and a method for pu...
|
|
WO/2018/108130A1 |
A process for the preparation of a novel androgen receptor antagonist is provided, comprising essentially conducting cyclization reaction of a compound of formula V to obtain a compound of formula VI. This method has the advantages of ea...
|
